On Jun. 8, 2021, the University of Oxford announced that the RECOVERY trial found aspirin does not improve survival for patients hospitalised with COVID-19.

Between November 2020 and March 2021, the RECOVERY trial included nearly 15,000 patients hospitalised with COVID-19 in an assessment of the effects of aspirin, which is widely used to reduce blood clotting in other diseases.